Arbaclofen in fragile X syndrome: results of phase 3 trials
Crossref DOI link: https://doi.org/10.1186/s11689-016-9181-6
Published Online: 2017-06-12
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Berry-Kravis, Elizabeth
Hagerman, Randi
Visootsak, Jeannie
Budimirovic, Dejan
Kaufmann, Walter E.
Cherubini, Maryann
Zarevics, Peter
Walton-Bowen, Karen
Wang, Paul
Bear, Mark F.
Carpenter, Randall L.
Funding for this research was provided by:
Seaside Therapeutics, Inc.
